Entecavir and mannatide drug composition and preparation method thereof

A technology of mannan peptide and entecavir, which is applied in the field of medicine to achieve good synergistic effect and pharmacological activity, and enhance immunity

Active Publication Date: 2015-10-28
FUJIAN COSUNTER PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on the combined use of Entecavir and mannan peptides in the prior art. The inventors combined Entecavir and mannan peptides and unexpectedly found that the two have a synergistic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Entecavir and mannatide drug composition and preparation method thereof
  • Entecavir and mannatide drug composition and preparation method thereof
  • Entecavir and mannatide drug composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1 Entecavir and mannan peptide pharmaceutical composition formulation prescription ratio

[0037] Table 1: The formulation ratio of entecavir and mannan peptide pharmaceutical composition for the treatment of viral hepatitis B, which can be used in both tablets and hard capsules.

[0038] The general manufacturing method for solid dosage forms is as follows:

[0039] 1. The proportioned entecavir, mannan peptide and excipients are mixed together;

[0040] 2. The homogeneous matter obtained in step 1 is further compacted into small particles;

[0041] 3. Lubricants such as magnesium stearate etc. are mixed with the granules obtained in the above step 2;

[0042] 4. The homogenate in step 3 is compressed into tablets or other solid dosage forms;

[0043] 5. If necessary, the coating liquid can be sprayed onto the tablet obtained in step 4 in the form of mist droplets.

[0044] When adopting hard capsule preparation, then the homogenate obtained in step 3 is d...

Embodiment 2

[0047] Prescription and preparation of embodiment 2 pharmaceutical composition tablet

[0048] prescription

[0049]

[0050] Preparation method: Weigh each component according to the prescription amount, mix thoroughly and evenly, granulate, and compress into tablets with a tablet machine.

Embodiment 3

[0051] Prescription and preparation of embodiment 3 pharmaceutical composition capsules

[0052] prescription

[0053]

[0054] Preparation method: weigh each component according to the prescription amount, sieve and dry, fully mix, granulate, and fill with hollow capsules to obtain capsules of the pharmaceutical composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an entecavir and mannatide drug composition and a preparation method thereof. The entecavir and mannatide drug composition is a drug capable of inhibiting virus replication and regeneration, enhances the immunity of a human body, and has remarkable treatment effect, has not any cross effect, has high safety and better anti-virus capability and can enhance the immunity of patients and the function of liver cell regeneration.

Description

technical field [0001] The present invention relates to the field of medicine, more specifically, to a pharmaceutical composition of entecavir and mannan peptide and a preparation method thereof. Background technique [0002] Hepatitis B is a disease of liver inflammation and necrosis caused by persistent infection of hepatitis B virus (HBV). Hepatitis B virus generally has no direct cytotoxic effect. The dynamic process of chronic HBV infection includes the interaction between the virus, the host's immune status and liver cells. Although the main mechanism of the infection has not been fully clarified, it is generally believed to be related to the low immune function of the body. Related, after HBV infection, immune response or immune regulatory dysfunction occurs, which leads to liver damage. Its serious clinical outcomes are decompensated cirrhosis and primary liver cancer. Therefore, it is of great significance to study the treatment of hepatitis B. [0003] Entecavir...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P31/20A61P37/04A61K31/522
Inventor 卢汉翔陈仕魁姚建堤周巧云陈彤彤苏葳张燕华
Owner FUJIAN COSUNTER PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap